<mxfile host="app.diagrams.net" modified="2024-12-01T00:00:00.000Z" agent="5.0" version="24.0.0" etag="xyz" type="device">
  <diagram name="Weldon-MedChem" id="weldon-main">
    <mxGraphModel dx="2200" dy="1800" grid="1" gridSize="10" guides="1" tooltips="1" connect="1" arrows="1" fold="1" page="1" pageScale="1" pageWidth="1600" pageHeight="1600" math="0" shadow="0">
      <root>
        <mxCell id="0"/>
        <mxCell id="1" parent="0"/>

        <!-- TITLE -->
        <mxCell id="title" value="MEDICINAL CHEMISTRY - Dr. Weldon&lt;br&gt;BPH/ED/UI Drug Structures | Osteoporosis Chemistry | Gonadal Hormones SAR" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;fontStyle=1;fontSize=18;align=center;verticalAlign=middle;" parent="1" vertex="1">
          <mxGeometry x="40" y="20" width="1520" height="80" as="geometry"/>
        </mxCell>

        <!-- SECTION 1: MALE HEALTH MED CHEM -->
        <mxCell id="male-section" value="SECTION 1: MALE HEALTH MED CHEM (BPH &amp; ED)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#dae8fc;strokeColor=#6c8ebf;fontStyle=1;fontSize=16;" parent="1" vertex="1">
          <mxGeometry x="40" y="130" width="750" height="50" as="geometry"/>
        </mxCell>

        <!-- PDE5 Inhibitors SAR -->
        <mxCell id="pde5-sar-box" value="PDE5 INHIBITORS - Structure-Activity Relationships" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#cfe2f3;strokeColor=#6c8ebf;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="60" y="210" width="350" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="pde5-core" value="Core Scaffold Requirements:&lt;br&gt;â€¢ Heterocyclic ring system&lt;br&gt;â€¢ Planar aromatic structure&lt;br&gt;â€¢ H-bond donors/acceptors&lt;br&gt;â€¢ Hydrophobic substituents&lt;br&gt;&lt;br&gt;Binding: Compete with cGMP for&lt;br&gt;PDE5 active site" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="60" y="265" width="170" height="155" as="geometry"/>
        </mxCell>

        <mxCell id="sildenafil-structure" value="Sildenafil (Viagra)&lt;br&gt;â€¢ Pyrazolopyrimidinone core&lt;br&gt;â€¢ Ethoxy group at N-position&lt;br&gt;â€¢ Piperazine ring with sulfonyl&lt;br&gt;â€¢ Poor PDE5/PDE6 selectivity&lt;br&gt;  â†’ blue vision (PDE6 in retina)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="240" y="265" width="170" height="120" as="geometry"/>
        </mxCell>

        <mxCell id="tadalafil-structure" value="Tadalafil (Cialis)&lt;br&gt;â€¢ Beta-carboline core&lt;br&gt;â€¢ Piperazinedione ring&lt;br&gt;â€¢ Methylenedioxy benzene&lt;br&gt;â€¢ Longer tÂ½ (17.5 hr)&lt;br&gt;â€¢ Better PDE selectivity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="240" y="400" width="170" height="110" as="geometry"/>
        </mxCell>

        <!-- Alpha-Blockers SAR -->
        <mxCell id="alpha-sar-box" value="ALPHA-1 BLOCKERS - BPH Drug Chemistry" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#cfe2f3;strokeColor=#6c8ebf;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="440" y="210" width="330" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="alpha-sar" value="General Structure:&lt;br&gt;â€¢ Aryl group (aromatic ring)&lt;br&gt;â€¢ Piperazine or similar amine&lt;br&gt;â€¢ Methoxy substituents&lt;br&gt;â€¢ Sulfonamide linkage&lt;br&gt;&lt;br&gt;Selectivity Key:&lt;br&gt;Alpha-1A selectivity â†“ CV effects" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="460" y="265" width="140" height="140" as="geometry"/>
        </mxCell>

        <mxCell id="tamsulosin-structure" value="Tamsulosin (Flomax)&lt;br&gt;â€¢ Sulfamoyl phenoxyethyl&lt;br&gt;â€¢ Piperidine ring&lt;br&gt;â€¢ High alpha-1A selectivity&lt;br&gt;  (prostate &gt;&gt; vasculature)&lt;br&gt;â€¢ Minimal orthostatic hypotension&lt;br&gt;&lt;br&gt;Key: Sulfonamide bridge critical" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="620" y="265" width="140" height="150" as="geometry"/>
        </mxCell>

        <!-- 5-ARI SAR -->
        <mxCell id="5ari-sar-box" value="5-ALPHA-REDUCTASE INHIBITORS" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#cfe2f3;strokeColor=#6c8ebf;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="60" y="540" width="350" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="finasteride-structure" value="Finasteride&lt;br&gt;â€¢ Azasteroid structure&lt;br&gt;â€¢ 4-Aza-3-oxo modification&lt;br&gt;â€¢ Selective for Type 2 5Î±-reductase&lt;br&gt;â€¢ Irreversible enzyme inhibitor&lt;br&gt;&lt;br&gt;SAR: Nitrogen at C4 mimics&lt;br&gt;testosterone transition state" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="60" y="595" width="170" height="135" as="geometry"/>
        </mxCell>

        <mxCell id="dutasteride-structure" value="Dutasteride&lt;br&gt;â€¢ Dual 4,6-Aza modification&lt;br&gt;â€¢ Inhibits Type 1 + Type 2&lt;br&gt;â€¢ More complete DHT suppression&lt;br&gt;  (â†“ serum DHT by 95%)&lt;br&gt;&lt;br&gt;Advantage: Broader inhibition&lt;br&gt;Disadvantage: Longer tÂ½" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="240" y="595" width="170" height="145" as="geometry"/>
        </mxCell>

        <!-- SECTION 2: URINARY & UI DRUG CHEMISTRY -->
        <mxCell id="ui-section" value="SECTION 2: URINARY &amp; UI DRUG CHEMISTRY" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5e8d4;strokeColor=#82b366;fontStyle=1;fontSize=16;" parent="1" vertex="1">
          <mxGeometry x="820" y="130" width="720" height="50" as="geometry"/>
        </mxCell>

        <!-- Antimuscarinics SAR -->
        <mxCell id="antimuscarinic-box" value="ANTIMUSCARINICS - M3 Receptor Antagonists" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5f5d5;strokeColor=#82b366;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="840" y="210" width="330" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="antimuscarinic-sar" value="Core Structure Requirements:&lt;br&gt;â€¢ Quaternary or tertiary amine&lt;br&gt;â€¢ Large hydrophobic groups&lt;br&gt;â€¢ Ester or amide linkage&lt;br&gt;â€¢ Distance from N to ester: ~5Ã…&lt;br&gt;&lt;br&gt;Selectivity: M3 &gt; M2&lt;br&gt;(bladder &gt; heart)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5f5d5;strokeColor=#82b366;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="840" y="265" width="160" height="140" as="geometry"/>
        </mxCell>

        <mxCell id="oxybutynin-structure" value="Oxybutynin&lt;br&gt;â€¢ Tertiary amine (CNS penetration)&lt;br&gt;â€¢ Cyclohexyl + phenyl groups&lt;br&gt;â€¢ Ester linkage&lt;br&gt;â€¢ Non-selective M3&lt;br&gt;&lt;br&gt;Side effects: Dry mouth,&lt;br&gt;constipation, confusion" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5f5d5;strokeColor=#82b366;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="1020" y="265" width="140" height="135" as="geometry"/>
        </mxCell>

        <mxCell id="darifenacin-structure" value="Darifenacin&lt;br&gt;â€¢ Pyrrolidine ring&lt;br&gt;â€¢ Benzofuran moiety&lt;br&gt;â€¢ HIGH M3 selectivity&lt;br&gt;â€¢ Less CNS effects&lt;br&gt;&lt;br&gt;Advantage: Fewer cognitive SE" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5f5d5;strokeColor=#82b366;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="1180" y="265" width="140" height="115" as="geometry"/>
        </mxCell>

        <mxCell id="solifenacin-structure" value="Solifenacin&lt;br&gt;â€¢ Quinuclidin-3-yl scaffold&lt;br&gt;â€¢ Tetrahydroisoquinoline&lt;br&gt;â€¢ Long tÂ½ (45-68 hr)&lt;br&gt;â€¢ Once-daily dosing" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5f5d5;strokeColor=#82b366;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="1340" y="265" width="140" height="95" as="geometry"/>
        </mxCell>

        <!-- Beta-3 Agonist -->
        <mxCell id="beta3-box" value="BETA-3 AGONIST - Mirabegron" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5f5d5;strokeColor=#82b366;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="840" y="430" width="330" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="mirabegron-structure" value="Mirabegron Structure:&lt;br&gt;â€¢ Phenylethylamine derivative&lt;br&gt;â€¢ Thiazole ring&lt;br&gt;â€¢ Selective beta-3 agonist&lt;br&gt;â€¢ NO anticholinergic effects&lt;br&gt;&lt;br&gt;MOA: Activates beta-3 on detrusor&lt;br&gt;â†’ Relaxation via cAMP&lt;br&gt;&lt;br&gt;Advantage: Safe for elderly&lt;br&gt;Warning: Can â†‘ BP" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5f5d5;strokeColor=#82b366;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="840" y="485" width="160" height="190" as="geometry"/>
        </mxCell>

        <!-- SECTION 3: OSTEOPOROSIS DRUG CHEMISTRY -->
        <mxCell id="bone-section" value="SECTION 3: OSTEOPOROSIS DRUG CHEMISTRY" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;fontStyle=1;fontSize=16;" parent="1" vertex="1">
          <mxGeometry x="40" y="770" width="750" height="50" as="geometry"/>
        </mxCell>

        <!-- Bisphosphonates -->
        <mxCell id="bisphos-box" value="BISPHOSPHONATES - P-C-P Core Structure" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f5e6ff;strokeColor=#9673a6;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="60" y="850" width="350" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="bisphos-core" value="Core Structure: P-C-P&lt;br&gt;â€¢ Two phosphonate groups&lt;br&gt;â€¢ Geminal (same carbon)&lt;br&gt;â€¢ Central carbon with R1, R2&lt;br&gt;&lt;br&gt;Critical SAR:&lt;br&gt;â€¢ P-C-P binds hydroxyapatite&lt;br&gt;â€¢ R1 = OH â†’ â†‘ bone affinity&lt;br&gt;â€¢ R2 = nitrogen-containing side chain&lt;br&gt;  â†’ â†‘ potency (1000Ã—)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f0e6ff;strokeColor=#9673a6;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="60" y="905" width="170" height="180" as="geometry"/>
        </mxCell>

        <mxCell id="alendronate-structure" value="Alendronate (Fosamax)&lt;br&gt;â€¢ R1 = OH&lt;br&gt;â€¢ R2 = 4-amino-butyl&lt;br&gt;â€¢ Nitrogen-containing bisphosphonate&lt;br&gt;&lt;br&gt;MOA: Inhibits farnesyl&lt;br&gt;pyrophosphate synthase&lt;br&gt;â†’ Disrupts osteoclast function" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f0e6ff;strokeColor=#9673a6;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="240" y="905" width="170" height="130" as="geometry"/>
        </mxCell>

        <mxCell id="risedronate-structure" value="Risedronate&lt;br&gt;â€¢ R1 = OH&lt;br&gt;â€¢ R2 = 3-pyridinyl&lt;br&gt;â€¢ Heterocyclic nitrogen&lt;br&gt;â€¢ High potency&lt;br&gt;â€¢ Better GI tolerability" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f0e6ff;strokeColor=#9673a6;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="240" y="1050" width="170" height="105" as="geometry"/>
        </mxCell>

        <mxCell id="zoledronate-structure" value="Zoledronate (IV)&lt;br&gt;â€¢ R2 = Imidazole ring&lt;br&gt;â€¢ Most potent bisphosphonate&lt;br&gt;â€¢ Annual IV infusion&lt;br&gt;â€¢ Used for Paget disease" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f0e6ff;strokeColor=#9673a6;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="60" y="1100" width="170" height="90" as="geometry"/>
        </mxCell>

        <!-- Denosumab -->
        <mxCell id="denosumab-box" value="DENOSUMAB - Monoclonal Antibody" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f5e6ff;strokeColor=#9673a6;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="440" y="850" width="330" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="denosumab-detail" value="Denosumab (Prolia)&lt;br&gt;â€¢ Fully human IgG2 monoclonal antibody&lt;br&gt;â€¢ Binds RANKL (receptor activator of&lt;br&gt;  nuclear factor kappa-B ligand)&lt;br&gt;â€¢ Prevents RANKL-RANK interaction&lt;br&gt;â€¢ Blocks osteoclast formation&lt;br&gt;&lt;br&gt;Advantage over bisphosphonates:&lt;br&gt;â€¢ No renal concerns&lt;br&gt;â€¢ SC injection every 6 months&lt;br&gt;â€¢ Rapid reversibility" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f0e6ff;strokeColor=#9673a6;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="440" y="905" width="170" height="200" as="geometry"/>
        </mxCell>

        <!-- Anabolic Agents -->
        <mxCell id="anabolic-box" value="ANABOLIC BONE AGENTS" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f5e6ff;strokeColor=#9673a6;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="440" y="1125" width="330" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="teriparatide-detail" value="Teriparatide (Forteo)&lt;br&gt;â€¢ Recombinant PTH(1-34)&lt;br&gt;â€¢ 34 amino acid N-terminal fragment&lt;br&gt;â€¢ ANABOLIC - builds bone&lt;br&gt;â€¢ Daily SC injection&lt;br&gt;â€¢ Max 2 years (â†‘ osteosarcoma risk&lt;br&gt;  in rat studies)&lt;br&gt;&lt;br&gt;MOA: Intermittent PTH exposure&lt;br&gt;â†’ â†‘ osteoblast activity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f0e6ff;strokeColor=#9673a6;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="440" y="1180" width="160" height="175" as="geometry"/>
        </mxCell>

        <mxCell id="romosozumab-detail" value="Romosozumab (Evenity)&lt;br&gt;â€¢ Monoclonal antibody&lt;br&gt;â€¢ Inhibits sclerostin&lt;br&gt;â€¢ DUAL action:&lt;br&gt;  1) â†‘ bone formation (anabolic)&lt;br&gt;  2) â†“ bone resorption&lt;br&gt;â€¢ Monthly SC injection Ã— 12 months&lt;br&gt;&lt;br&gt;WARNING: CV risk (MI, stroke)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f0e6ff;strokeColor=#9673a6;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="620" y="1180" width="140" height="160" as="geometry"/>
        </mxCell>

        <!-- SECTION 4: GONADAL HORMONE SAR -->
        <mxCell id="hormone-section" value="SECTION 4: GONADAL HORMONE SAR PRINCIPLES" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f8cecc;strokeColor=#b85450;fontStyle=1;fontSize=16;" parent="1" vertex="1">
          <mxGeometry x="820" y="710" width="720" height="50" as="geometry"/>
        </mxCell>

        <!-- Estrogens -->
        <mxCell id="estrogen-sar-box" value="ESTROGEN SAR - Critical Features" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="840" y="790" width="330" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="estrogen-sar" value="Estradiol (E2) - Native Structure:&lt;br&gt;â€¢ C18 steroid&lt;br&gt;â€¢ Aromatic A-ring (REQUIRED)&lt;br&gt;â€¢ 3-OH phenolic (REQUIRED)&lt;br&gt;â€¢ 17Î²-OH (REQUIRED for max potency)&lt;br&gt;&lt;br&gt;Synthetic Modifications:&lt;br&gt;â€¢ 17Î±-Ethinyl â†’ oral activity&lt;br&gt;  (Ethinyl Estradiol)&lt;br&gt;â€¢ 17Î²-Esters â†’ depot IM formulations&lt;br&gt;  (Valerate, Cypionate)&lt;br&gt;&lt;br&gt;Key: Cannot modify A-ring aromaticity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d79b00;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="840" y="845" width="160" height="210" as="geometry"/>
        </mxCell>

        <mxCell id="serm-sar" value="SERMs - Tamoxifen/Raloxifene:&lt;br&gt;â€¢ Triphenylethylene core&lt;br&gt;â€¢ Basic amine side chain&lt;br&gt;â€¢ Large bulky substituents&lt;br&gt;â€¢ Block ER-coactivator binding&lt;br&gt;&lt;br&gt;Tissue selectivity mechanism:&lt;br&gt;â€¢ Alter ER conformation&lt;br&gt;â€¢ Prevent chromatin binding&lt;br&gt;â€¢ Antagonist in breast&lt;br&gt;â€¢ Agonist in bone" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d79b00;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="1020" y="845" width="140" height="180" as="geometry"/>
        </mxCell>

        <mxCell id="ai-sar" value="Aromatase Inhibitors:&lt;br&gt;â€¢ Nonsteroidal triazoles&lt;br&gt;â€¢ N-4 nitrogen binds heme&lt;br&gt;â€¢ Competitive inhibition&lt;br&gt;&lt;br&gt;Examples:&lt;br&gt;â€¢ Anastrozole (Arimidex)&lt;br&gt;â€¢ Letrozole (Femara)&lt;br&gt;&lt;br&gt;MOA: Block CYP19 (aromatase)&lt;br&gt;â†’ â†“ testosterone â†’ estrogen" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d79b00;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="1180" y="845" width="140" height="180" as="geometry"/>
        </mxCell>

        <!-- Progestins -->
        <mxCell id="progestin-sar-box" value="PROGESTIN SAR - Generations &amp; Modifications" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="840" y="1075" width="480" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="progestin-sar" value="Progesterone (C21) - Native:&lt;br&gt;â€¢ C21 steroid&lt;br&gt;â€¢ 3-Keto, 4-ene (Î”4)&lt;br&gt;â€¢ 20-Keto&lt;br&gt;â€¢ Poor oral bioavailability&lt;br&gt;&lt;br&gt;1st Gen (Estranes):&lt;br&gt;â€¢ Remove C19 methyl&lt;br&gt;â€¢ Add 17Î±-ethinyl â†’ oral activity&lt;br&gt;â€¢ Norethindrone (NET)&lt;br&gt;â€¢ Some androgenic activity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d79b00;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="840" y="1130" width="150" height="170" as="geometry"/>
        </mxCell>

        <mxCell id="progestin-2nd" value="2nd Gen (Gonanes):&lt;br&gt;â€¢ 13-Ethyl instead of 13-methyl&lt;br&gt;â€¢ Levonorgestrel (LNG)&lt;br&gt;â€¢ â†‘â†‘ Progestational potency&lt;br&gt;â€¢ Most androgenic&lt;br&gt;&lt;br&gt;3rd Gen:&lt;br&gt;â€¢ Desogestrel, Gestodene&lt;br&gt;â€¢ Less androgenic&lt;br&gt;â€¢ â†‘ VTE risk" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d79b00;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="1010" y="1130" width="150" height="145" as="geometry"/>
        </mxCell>

        <mxCell id="progestin-4th" value="4th Gen:&lt;br&gt;â€¢ Drospirenone (spironolactone-&lt;br&gt;  derived)&lt;br&gt;â€¢ Anti-mineralocorticoid&lt;br&gt;â€¢ Anti-androgenic&lt;br&gt;â€¢ Monitor Kâº&lt;br&gt;&lt;br&gt;â€¢ Dienogest (ultra-selective PR)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d79b00;align=left;fontSize=11;fontStyle=1;" parent="1" vertex="1">
          <mxGeometry x="1180" y="1130" width="140" height="130" as="geometry"/>
        </mxCell>

        <!-- Androgens -->
        <mxCell id="androgen-sar-box" value="ANDROGEN SAR - Testosterone Modifications" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontStyle=1;fontSize=13;" parent="1" vertex="1">
          <mxGeometry x="1350" y="845" width="180" height="40" as="geometry"/>
        </mxCell>

        <mxCell id="androgen-sar" value="Testosterone (C19):&lt;br&gt;â€¢ C19 steroid&lt;br&gt;â€¢ 3-Keto, 4-ene&lt;br&gt;â€¢ 17Î²-OH&lt;br&gt;&lt;br&gt;Modifications:&lt;br&gt;â€¢ 17Î±-Methyl â†’ oral activity&lt;br&gt;  (HEPATOTOXIC)&lt;br&gt;â€¢ 17Î²-Esters â†’ depot IM&lt;br&gt;  (Enanthate, Cypionate)&lt;br&gt;&lt;br&gt;Anabolic steroids:&lt;br&gt;â€¢ Remove C19 â†’ â†“ androgenic&lt;br&gt;â€¢ Retain anabolic effects&lt;br&gt;â€¢ Oxandrolone, Nandrolone" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d79b00;align=left;fontSize=11;" parent="1" vertex="1">
          <mxGeometry x="1350" y="900" width="180" height="215" as="geometry"/>
        </mxCell>

        <!-- HIGH-YIELD MED CHEM PEARLS -->
        <mxCell id="pearls-section" value="HIGH-YIELD MED CHEM PEARLS" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d6b656;fontStyle=1;fontSize=16;" parent="1" vertex="1">
          <mxGeometry x="40" y="1350" width="1500" height="50" as="geometry"/>
        </mxCell>

        <mxCell id="pearl1" value="ðŸ”¬ 17Î±-Ethinyl group:&lt;br&gt;Blocks 17Î²-OH oxidation â†’ oral activity&lt;br&gt;(EE, NET, norethindrone)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="60" y="1420" width="180" height="70" as="geometry"/>
        </mxCell>

        <mxCell id="pearl2" value="ðŸ”¬ P-C-P bisphosphonate core:&lt;br&gt;Binds hydroxyapatite in bone&lt;br&gt;Nitrogen in R2 â†’ 1000Ã— â†‘ potency" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="260" y="1420" width="180" height="70" as="geometry"/>
        </mxCell>

        <mxCell id="pearl3" value="ðŸ”¬ Aromatic A-ring REQUIRED:&lt;br&gt;Estrogenic activity absolutely requires&lt;br&gt;phenolic OH at C3" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="460" y="1420" width="180" height="70" as="geometry"/>
        </mxCell>

        <mxCell id="pearl4" value="ðŸ”¬ 13-Ethyl vs 13-Methyl:&lt;br&gt;Gonanes (13-ethyl) have dramatically&lt;br&gt;â†‘ progestational potency vs estranes" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="660" y="1420" width="180" height="70" as="geometry"/>
        </mxCell>

        <mxCell id="pearl5" value="ðŸ”¬ Azasteroid modification:&lt;br&gt;Nitrogen at C4 mimics transition state&lt;br&gt;â†’ 5Î±-reductase inhibition (Finasteride)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="860" y="1420" width="180" height="70" as="geometry"/>
        </mxCell>

        <mxCell id="pearl6" value="ðŸ”¬ Triazole nitrogen:&lt;br&gt;N-4 binds CYP19 heme â†’ aromatase&lt;br&gt;inhibition (Letrozole, Anastrozole)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="1060" y="1420" width="180" height="70" as="geometry"/>
        </mxCell>

        <mxCell id="pearl7" value="ðŸ”¬ Beta-3 selectivity:&lt;br&gt;Mirabegron activates bladder detrusor&lt;br&gt;WITHOUT cardiovascular beta-1/2 effects" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="1260" y="1420" width="180" height="70" as="geometry"/>
        </mxCell>

        <mxCell id="pearl8" value="ðŸ”¬ Alpha-1A selectivity:&lt;br&gt;Tamsulosin's sulfonamide bridge gives&lt;br&gt;prostate &gt;&gt; vascular selectivity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="160" y="1510" width="180" height="60" as="geometry"/>
        </mxCell>

        <mxCell id="pearl9" value="ðŸ”¬ RANKL-RANK blockade:&lt;br&gt;Denosumab mAb prevents osteoclast&lt;br&gt;maturation (no renal concerns)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" parent="1" vertex="1">
          <mxGeometry x="360" y="1510" width="180" height="60" as="geometry"/>
        </mxCell>

        <!-- LEGEND -->
        <mxCell id="legend-title" value="LEGEND" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f5f5f5;strokeColor=#666666;fontStyle=1;fontSize=12;" parent="1" vertex="1">
          <mxGeometry x="1020" y="485" width="520" height="30" as="geometry"/>
        </mxCell>

        <mxCell id="legend1" value="Blue = Male health (BPH/ED)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#dae8fc;strokeColor=#6c8ebf;fontSize=10;" parent="1" vertex="1">
          <mxGeometry x="1020" y="530" width="160" height="30" as="geometry"/>
        </mxCell>

        <mxCell id="legend2" value="Purple = Bone/osteoporosis" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;fontSize=10;" parent="1" vertex="1">
          <mxGeometry x="1200" y="530" width="160" height="30" as="geometry"/>
        </mxCell>

        <mxCell id="legend3" value="Pink = Gonadal hormones" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f8cecc;strokeColor=#b85450;fontSize=10;" parent="1" vertex="1">
          <mxGeometry x="1380" y="530" width="160" height="30" as="geometry"/>
        </mxCell>

        <mxCell id="legend4" value="Green = Urinary/UI drugs" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5e8d4;strokeColor=#82b366;fontSize=10;" parent="1" vertex="1">
          <mxGeometry x="1020" y="575" width="160" height="30" as="geometry"/>
        </mxCell>

        <mxCell id="legend5" value="Orange = High-yield chem pearls" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=10;" parent="1" vertex="1">
          <mxGeometry x="1200" y="575" width="160" height="30" as="geometry"/>
        </mxCell>

        <mxCell id="legend6" value="Yellow = SAR/mechanism details" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#fff2cc;strokeColor=#d6b656;fontSize=10;" parent="1" vertex="1">
          <mxGeometry x="1380" y="575" width="160" height="30" as="geometry"/>
        </mxCell>

      </root>
    </mxGraphModel>
  </diagram>
</mxfile>
